Skip to main content
. 2015 Mar 31;26(6):1831–1840. doi: 10.1007/s00198-015-3084-3

Fig. 1.

Fig. 1

Kaplan-Meier persistence curves for treatment with anti-osteoporosis drugs after a recent fracture for a the total study population, b stratified by age category, c stratified by type of fracture—discontinuation was defined as a treatment gap of >90 days and switching between anti-osteoporosis drugs or dosage regimes was allowed when this occurred within the treatment gap